期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

可溶性尿激酶受体的表达、纯化和结晶 被引量：3

The Expression, Purification and Crystallization of Monomeric Soluble Human Urokinase Receptor
下载PDF
导出
摘要 克隆尿激酶受体可溶区域(suPAR)到果蝇胚胎细胞分泌表达载体pMT/Bip/v5-his,重组质粒与pCoHygro共转染果蝇S2细胞,筛选多拷贝稳定表达细胞系suPARS2.suPAR表达蛋白经尿激酶N端片段亲和柱、ResourceQ阴离子交换柱两步纯化后,得到高纯度的、稳定的suPAR单体.纯化后的蛋白质,与其抗体ATN615及尿激酶N端片段结构域等摩尔混合,浓缩至10g/L,以透析法进行该三元复合物晶体生长,获得衍射分辨率为1.9#的蛋白质晶体. Soluble form of human urokinase receptor was cloned into Drosophila Schneider 2 secretion expression vector pMT/Bip/vS-his, and co-transfected with pCoHygro into S2 cells, to establish stably S2 cells line. The expressed suPAR from such procedure tends to form oligomer and is unstable, presenting difficulties for its structural studies. Here a purification procedure that yields monomeric suPAR was reported. SuPAR obtained through such procedure is monomeric and quite stable. SuPAR complex with amino terminal fragment （ATF） of uPA and an anti-suPAR antibody （ATN615） was crystallized by dialysis method into diffracting crystals （1.9A）.
作者 袁彩 淮清 卞传兵 黄明东
机构地区 中国科学院福建物质结构研究所 Center for Haemostasis and Thrombosis Research 中国科学院研究生院
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2006年第3期277-281,共5页 Progress In Biochemistry and Biophysics
基金 国家自然科学基金重点项目(30430190)~~
关键词 可溶性尿激酶受体 纯化 复合物结晶 soluble human urokinase receptor, S2 cells, purification, crystallization
分类号 Q71 [生物学—分子生物学]
  • 相关文献

参考文献9

  • 1卞传兵,袁彩,赵更香,李永东,黄明东.尿激酶／尿激酶受体结构研究进展[J].中国生物工程杂志,2005,25(B04):144-147. 被引量：4
  • 2Ploug M.Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.Curr Pharm Des,2003,9 (19):1499～1528
  • 3Bdeir K,Kuo A,Mazar A,et al.A region in domain Ⅱ of the urokinase receptor required for urokinase binding.J Biol Chem,2000,275 (37):28532～28538
  • 4Tarui T,Mazar A P,Cines D B,et al.Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.J Biol Chem,2001,276 (6):3983～3990
  • 5Gardsvoll H,Wemer F,Sondergaard L,et al.Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.Protein Expr Purif,2004,34 (2):284～295
  • 6Hansen L V,Gardsvoll H,Nielsen B S,et al.Structural analysis and tissue localization of human C4.4A:a protein homologue of the urokinase receptor.Biochem J,2004,380 (Pt 3):845～857
  • 7Ploug M,Kjalke M,Ronne E,et al.Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator.A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.J Biol Chem,1993,268 (23):17539～17546
  • 8Huang M,Mazar A P,Parry G,et al.Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1 ～143).Acta Crystallogr D Biol Crystallogr,2005,61 (Pt 6):697～700
  • 9Huai Q,Mazar A,Kuo A,et al.Structure of human urokinase plasminogen activator in complex with its receptor.Science,2006,311 (5761):656～659

二级参考文献25

  • 1Vassalli J D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol, 1985,100 (1) :86 - 92.
  • 2Vassalli J D, Sappino A P, Belin D. The plasminogen activator/plasmin system. J Clin Invest, 1991,88 (4) :1067 - 1072.
  • 3Yamamoto K, Loskutoff D J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type hut not tissue-type plasminogen activator. J Clin Invest, 1996,97 (11) :2440 - 2451.
  • 4Davis J,Wagner M R, Zhang W, et al. Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator(uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem, 2003,278 (21) : 19054 - 19061.
  • 5De Bock C E, Wang Y. Clinical significance of urokina-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev,2004,24 (1) : 13 - 39.
  • 6Pierga J Y, Bonneton C, Magdelenat H, et al. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer,2O04.
  • 7Wilhelm O, Weidle U, Hohl S, et al. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA).Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett, 1994,337 (2) : 131 - 134.
  • 8Bruse C, Radu D, Bergqvist A. In situ localization of mRNA for the fibrinolytic factors uPA. PA1-I and uPAR in endometriotic and endometrial tissue. Mol Hum Reprod, 2004,10 (3):159 - 166.
  • 9Uszynski M, Perlik M, Uszynski W, et al. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues:Measurements and clinical implications. Eur J Obstet Gynecol Reprod Biol, 2004,114 (1) :54 - 58.
  • 10Xing R H, Rabbani S A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer, 1996,67 (3) :423 - 429.

共引文献3

同被引文献39

引证文献3

二级引证文献3

生物化学与生物物理进展
2006年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部